The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | MAIA & TOURMALINE-MM3: updates in newly diagnosed multiple myeloma
In this interview, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, discusses the Phase III MAIA study (NCT02252172) that aims to further establish the role of daratumumab in the treatment of transplant-ineligible newly diagnosed multiple myeloma (NDMM). Dr Raje also discusses her views on the TOURMALINE-MM3 trial (NCT02181413), showing that maintenance therapy with ixazomib, an oral proteasome inhibitor, was found to significantly prolong progression-free survival following autologous stem cell transplantation in NDMM.
